TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03040063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard optimal therapy (OPT)
Description: 1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Unfractionated heparin 70-80 IU/kg i.a.~5. insertion of strait flush catheter for local thrombolysis~6. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~7. control angiography in 12 hrs or according to clinical status and symptoms~8. repeated angiography in24 hrs~9. Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm.
Study: NCT01385098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 and Calcium
Description: 1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
Study: NCT00464841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural
Description: 0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tsui Test for intrathecal catheter
Description: 0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
Study: NCT02135848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01005355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B
Description: Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
Study: NCT03235245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Ipilimumab
Description: nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Description: nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib
Description: encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
Study: NCT03536689

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amniotic fluid index
Description: Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amniotic fluid index
Description: Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
Study: NCT00598585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra)
Description: 25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills 3X/day for 6 weeks
Study: NCT01522391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPK-060 1% ointment
Description: DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DPK-060 ointment
Description: Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
Study: NCT05752591

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic testing
Description: Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
Study: NCT04185194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: transmission of the drug molecules to the underlying muscles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: transmission of the drug molecules to the underlying muscles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed ultrasound
Description: using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed ultrasound
Description: using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: especially designed physical therapy program
Description: by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: especially designed physical therapy program
Description: by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: especially designed physical therapy program
Description: by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
Study: NCT02896959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Study: NCT02067065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-anesthesiologist propofol sedation
Description: Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol sedation administered by an anesthesiologist
Description: Propofol sedation by an anesthesiologist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
Study: NCT00554840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
Study: NCT02492789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INCSHR01210 injection
Description: Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study.
Study: NCT03621111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-counseling
Description: After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient self-administered questionnaire
Description: The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pills counts
Description: At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
Study: NCT02831894

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0% Hypnotic Medication Taper
Description: Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% Hypnotic Medication Taper
Description: Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% Hypnotic Medication Taper
Description: Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
Study: NCT01173874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
Study: NCT04465513

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard of Care + CARDIO
Description: Combination of dietary supplement with clinical care

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Best Standard of Care
Description: Combination of placebo with clinical care
Study: NCT02948244

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02815475

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric powder
Study: NCT01488994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX326
Description: All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX326
Description: All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
Study: NCT01719718

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of hernia defect.
Description: Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
Study: NCT03547934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused ElectroMagnetic system.
Description: The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
Study: NCT01092962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 1200mg/m²/jour in two divided doses during 18 months
Study: NCT01918033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine 5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine 5 mg tablets
Study: NCT04208048

Intervention type: DEVICE
Intervention: FLXfit 15TM device
Description: In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
Study: NCT04385225

Intervention type: OTHER
Group type: OTHER
Intervention: Longitudinal follow-up
Description: Longitudinal hearing, vestibular and cognitive follow-up

Intervention type: OTHER
Group type: OTHER
Intervention: Longitudinal follow-up
Description: Longitudinal hearing, vestibular and cognitive follow-up

Intervention type: OTHER
Group type: OTHER
Intervention: Longitudinal follow-up
Description: Longitudinal hearing, vestibular and cognitive follow-up

Intervention type: OTHER
Group type: OTHER
Intervention: Longitudinal follow-up
Description: Longitudinal hearing, vestibular and cognitive follow-up

Intervention type: OTHER
Group type: OTHER
Intervention: Longitudinal follow-up
Description: Longitudinal hearing, vestibular and cognitive follow-up

Intervention type: OTHER
Group type: OTHER
Intervention: Longitudinal follow-up
Description: Longitudinal hearing, vestibular and cognitive follow-up
Study: NCT02345096

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces cerevisiae
Study: NCT01719718

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No closure of the hernia defect.
Description: Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
Study: NCT00650715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands
Description: Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Whole-body vibration exercise
Description: Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
Study: NCT02345096

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00121641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg, Once daily (24 weeks short term \[ST\], 42 months long term \[LT\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Saxagliptin
Description: Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablets, Oral, 500 mg, daily (42 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Metformin
Description: Tablets, Oral, 0 mg, daily (42 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Metformin
Description: Tablets, Oral, 0 mg, daily (42 months LT)
Study: NCT02013648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Study: NCT00726076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebEase
Description: Computer-based epilepsy self-management program~The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebEase
Description: Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
Study: NCT01485640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
Study: NCT04299204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolitotomy
Description: Pediatric PCNL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolitotomy
Description: Pediatric PCNL
Study: NCT03232281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate PR 3-month
Description: 15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin Acetate PR 1-month
Description: 3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
Study: NCT05118451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 d visualization technology
Description: 3D visualization technology refers to the conversion of 2d imaging data such as CT and MR into 3D stereoscopic images through computer calculation, analysis and reconstruction, visually separating the shapes and spatial distribution features of targets such as liver, blood vessels and tumors directly, accurately and quickly to present three-dimensional views. Combined with transparency, rotation, scaling and measurement techniques, real-time and interactive 3D dynamic analysis of 3d visual model is carried out. In addition, the computer was used to simulate the operation, and the feasible surgical plan was discussed. The best surgical plan was selected based on the patient's individual data.
Study: NCT01918033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to desloratadine 5 mg tablets
Study: NCT01403246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide; Chlorambucil
Description: MTD of lenalidomide given in combination with chlorambucil
Study: NCT01365507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
Study: NCT01918033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to desloratadine 5 mg tablets
Study: NCT02311413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
Study: NCT02848014

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing task
Study: NCT00777647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened soft drink
Description: One litre a day for six months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspartame-sweetened soft drink
Description: One litre a day for six months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-skimmed milk
Description: One litre a day for six months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: One litre a day for six months.
Study: NCT02974296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: non invasive brain stimulation approach

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: non invasive brain stimulation approach
Study: NCT03195114

Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodality Imaging and Biomarkers
Description: Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
Study: NCT02327182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-4666
Study: NCT02105610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane, isoflurane, sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: total intravenous anesthetics